Rifamycin

DB11753ApprovedInvestigationalWithdrawnSmall moleculeRifamycin Antibacterial

Rifamycin is an antibacterial used to treat traveler's diarrhea. Rifamycin is the prime member of the rifamycin family which are represented by drugs that are a product of fermentation from the gram-positive bacterium Amycolatopsis mediterranei, also known as Streptomyces mediterranei.

Mechanism: Rifamycins, as well as all the other members of this group, present an antibacterial mechanism of action related to the inhibition of RNA synthesis. This mechanism of action is done by the strong binding to the DNA-dependent RNA polymerase of prokaryotes. The inhibition of the RNA synthesis is thought to be related with the initiation phase of the process and to involve stacking interactions between the naphthalene ring and the aromatic moiety in the polymerase. As well, it has been suggested that the presence of zinc atoms in the polymerase allows for the binding of phenolic -OH groups of the naphthalene ring.
In eukaryotic cells, the binding is significantly reduced making them at least 100 to 10,000 times less sensitive to the action of rifamycins. The members of the rifamycin family present the same mechanism of action and the structural modifications are usually related to pharmacokinetic properties as well as to the interaction with eukaryotic cells.
Curator reviewed · 2 references
Primary indication: Rifamycin is indicated for the treatment of adult patients with travelers' diarrhea caused by noninvasive strains of E. coli.Curator reviewed · 2 structured indications
Formula / weight: C₃₇H₄₇NO₁₂ · 697.778 g/mol (avg)
First approval: United States, 2019
Also known as: Rifamicine SV · Rifamycin SV · Rifomycin SV
Code names: M-14

Resolves to

Compound

UNIIDU69T8ZZPACAS6998-60-3ChEMBLCHEMBL437765ChEBI29673KEGGD02549

Clinical / RWD

RxNorm35616ATCA07AA13ATCD06AX15ATCJ04AB03

Structure

InChIKeyHJYYPODYNSCCOU-ODRIEIDWSA-NSMILES

CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C)C(O)=C4C(O)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C=C(O)C4=C3C2=O

Targets

P0A8V2rpoBP0A7Z4rpoAP0A8T7rpoCP9WGY7rpoCP9WGY9rpoB

Transporters

P46721SLCO1A2Q9Y6L6SLCO1B1Q9NPD5SLCO1B3Q92959SLCO2A1O94956SLCO2B1Q96FL8SLC47A1P08183ABCB1

What you can answer from here — as of September 23, 2026

5Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

7TransportersSubstrate / inhibitor direction, not just membership

Listed above

96Drug interactionsStructured to mechanism, not free text

16Clinical trialsPhase, status and sponsor resolved per trial

2Structured indicationsCondition, population, route and combination as fields, not prose

1ContraindicationEach with its own population and attribute set

39Marketed productsAcross 4 countries and 17 labellers

5ATC codesIncluding every combination product, plus 52 drug categories

35+ReferencesStructured and connected to the statements they support

Which drugs share a target with Rifamycin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account